ClinConnect ClinConnect Logo
Search / Trial NCT04397484

Prospective RCT Lidocaine & Levobupivacaine on Block Dynamics After Subparaneural Popliteal Sciatic Nerve Block

Launched by CHINESE UNIVERSITY OF HONG KONG · May 20, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Rct Lidocaine (Xylocaine) Vs Levobupivacaine Sciatic Nerve Block

ClinConnect Summary

This clinical trial is investigating the effects of two different local anesthetics, lidocaine and levobupivacaine, when injected near the sciatic nerve in the back of the knee, which is often done to help manage pain during foot or ankle surgeries. The researchers want to find out if using lidocaine helps patients feel ready for surgery faster compared to levobupivacaine. They believe that injecting lidocaine below a specific point of the nerve may speed up the process of getting the area numb.

To participate in this study, individuals should be adults aged between 18 and 80 who are scheduled for elective foot surgery and are in good health (ASA physical status I-III). However, people who are pregnant, have certain health conditions, or have had previous surgeries in that area may not be eligible. Participants will receive either lidocaine or levobupivacaine before their surgery, and the researchers will monitor how quickly the anesthesia takes effect and how effective it is. This trial aims to improve the way pain is managed for patients undergoing these types of surgeries.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • American Society of Anesthesiologists (ASA) physical status I-III
  • adult and scheduled to undergo elective forefoot surgery under regional anaesthesia
  • Exclusion Criteria:
  • patient refusal
  • ASA physical status \> III
  • pregnancy
  • neuromuscular disorder
  • prior surgery in the popliteal fossa
  • coagulopathy
  • allergy to local anaesthetic drugs
  • skin infection at the site of needle insertion

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Shatin, New Territories, Hong Kong

Patients applied

0 patients applied

Trial Officials

Manoj K Karmakar, MD

Principal Investigator

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials